Genentech Inc. is taking another stab at the pain market, signing on very early to Kineta Chronic Pain LLC's nicotinic acetylcholine receptor alpha 9/10 antagonist program. The biotech thinks it may have struck on a drug target that may not only offer a safer approach to pain therapy than opioid receptor drugs, but could yield disease-modifying therapies as well.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?